Kenneth A Bauer

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology
    Kenneth A Bauer
    Department of Medicine, Harvard Medical School, and Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Chest 124:364S-370S. 2003
  2. ncbi request reprint Reversal of antithrombotic agents
    Kenneth A Bauer
    Department of Medicine, Beth Israel Deaconess Medical Center and VA Boston Healthcare System, Boston, Massachusetts 02215, USA
    Am J Hematol 87:S119-26. 2012
  3. ncbi request reprint Role of thrombophilia in deciding on the duration of anticoagulation
    Kenneth A Bauer
    Veterans Administration Boston Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02132, USA
    Semin Thromb Hemost 30:633-7. 2004
  4. ncbi request reprint Targeted inhibition of coagulation: oral agents show promise in phase III trials
    K A Bauer
    VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02130, USA
    J Thromb Haemost 5:2175-7. 2007
  5. ncbi request reprint Low intensity warfarin: is it clinically useful in venous thromboembolism management?
    Kenneth A Bauer
    VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Br J Haematol 127:155-8. 2004
  6. ncbi request reprint New anticoagulants: anti IIa vs anti Xa--is one better?
    Kenneth A Bauer
    VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Thromb Thrombolysis 21:67-72. 2006
  7. doi request reprint Long-term management of venous thromboembolism: a 61-year-old woman with unprovoked venous thromboembolism
    Kenneth A Bauer
    Harvard Medical School, and Beth Israel Deaconess Medical Center, Boston, Massachusetts, Boston, MA 02492, USA
    JAMA 305:1336-45. 2011
  8. doi request reprint Duration of anticoagulation: applying the guidelines and beyond
    Kenneth A Bauer
    Hematology Section, VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, MA 02215, USA
    Hematology Am Soc Hematol Educ Program 2010:210-5. 2010
  9. ncbi request reprint New anticoagulants
    Kenneth A Bauer
    VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Curr Opin Hematol 15:509-15. 2008
  10. ncbi request reprint Fondaparinux: a new synthetic and selective inhibitor of Factor Xa
    Kenneth A Bauer
    Harvard Medical School, Hematology Section, VA Boston Healthcare System, and Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Best Pract Res Clin Haematol 17:89-104. 2004

Detail Information

Publications59

  1. ncbi request reprint New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology
    Kenneth A Bauer
    Department of Medicine, Harvard Medical School, and Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Chest 124:364S-370S. 2003
    ..Fondaparinux has been approved for use in thromboprophylaxis after major orthopedic surgery, where it has demonstrated its efficacy compared to a low-molecular-weight heparin. Its clinical development in other indications is ongoing...
  2. ncbi request reprint Reversal of antithrombotic agents
    Kenneth A Bauer
    Department of Medicine, Beth Israel Deaconess Medical Center and VA Boston Healthcare System, Boston, Massachusetts 02215, USA
    Am J Hematol 87:S119-26. 2012
    ..This review describes available and future options for the reversal of the effects of anticoagulants, in particular the new oral agents and discusses current management strategies for bleeding events in clinical practice...
  3. ncbi request reprint Role of thrombophilia in deciding on the duration of anticoagulation
    Kenneth A Bauer
    Veterans Administration Boston Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02132, USA
    Semin Thromb Hemost 30:633-7. 2004
    ....
  4. ncbi request reprint Targeted inhibition of coagulation: oral agents show promise in phase III trials
    K A Bauer
    VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02130, USA
    J Thromb Haemost 5:2175-7. 2007
  5. ncbi request reprint Low intensity warfarin: is it clinically useful in venous thromboembolism management?
    Kenneth A Bauer
    VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Br J Haematol 127:155-8. 2004
    ....
  6. ncbi request reprint New anticoagulants: anti IIa vs anti Xa--is one better?
    Kenneth A Bauer
    VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Thromb Thrombolysis 21:67-72. 2006
    ..A number of oral direct factor Xa inhibitors as well as other oral direct thrombin inhibitors are in clinical development for the prevention and treatment of thrombosis...
  7. doi request reprint Long-term management of venous thromboembolism: a 61-year-old woman with unprovoked venous thromboembolism
    Kenneth A Bauer
    Harvard Medical School, and Beth Israel Deaconess Medical Center, Boston, Massachusetts, Boston, MA 02492, USA
    JAMA 305:1336-45. 2011
    ..The case of Ms W, a woman with unprovoked venous thromboembolism and hemorrhagic event while receiving anticoagulation, is used to illustrate clinical decision making to determine ongoing treatment...
  8. doi request reprint Duration of anticoagulation: applying the guidelines and beyond
    Kenneth A Bauer
    Hematology Section, VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, MA 02215, USA
    Hematology Am Soc Hematol Educ Program 2010:210-5. 2010
    ..The potential impact of having a nonremovable inferior vena caval filter will also be addressed...
  9. ncbi request reprint New anticoagulants
    Kenneth A Bauer
    VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Curr Opin Hematol 15:509-15. 2008
    ..New anticoagulants have been developed that selectively inhibit thrombin or factor Xa, and have predictable dose-response relationships...
  10. ncbi request reprint Fondaparinux: a new synthetic and selective inhibitor of Factor Xa
    Kenneth A Bauer
    Harvard Medical School, Hematology Section, VA Boston Healthcare System, and Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Best Pract Res Clin Haematol 17:89-104. 2004
    ..Other trials have demonstrated that fondaparinux is efficacious in the prevention of VTE in other patient populations at risk of thrombosis and in the treatment of symptomatic VTE...
  11. ncbi request reprint A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialist
    Kenneth A Bauer
    Department of Medicine, VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J South Orthop Assoc 11:197-202. 2002
    ..Fondaparinux has demonstrated its efficacy compared to a widely used low-molecular-weight heparin in a number of thromboprophylaxis trials after major orthopedic surgery and is approved for use in this setting...
  12. pmc Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study)
    Jeffrey I Zwicker
    Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Br J Haematol 160:530-7. 2013
    ..Enoxaparin demonstrated a clear trend towards reducing the rate of VTE in patients with elevated levels of TFMP, with an overall rate of VTE similar in magnitude to the lower TFMP group...
  13. ncbi request reprint Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures
    Barbara A Konkle
    Department of Medicine, University of Pennsylvannia School of Medicine, Philadelphia, 19104, USA
    Transfusion 43:390-4. 2003
    ..For this reason, replacement with AT concentrate has been used when anticoagulation is interrupted. A new recombinant human AT concentrate, produced using transgenic technology, has recently been developed...
  14. ncbi request reprint Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis
    Kenneth A Bauer
    Hematology Division, VA Boston HealthCare System and Beth Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Am J Orthop (Belle Mead NJ) 31:4-10. 2002
    ....
  15. ncbi request reprint Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism
    Kenneth A Bauer
    VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Curr Opin Pulm Med 8:398-404. 2002
    ..Fondaparinux also appears to be a very promising candidate for the treatment of patients with existing VTE...
  16. ncbi request reprint The thrombophilias: well-defined risk factors with uncertain therapeutic implications
    K A Bauer
    From Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts, USA
    Ann Intern Med 135:367-73. 2001
    ....
  17. ncbi request reprint D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism
    S Shrivastava
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, MA, USA
    J Thromb Haemost 4:1208-14. 2006
    ..Elevated plasma D-dimer and factor VIII coagulant activity (FVIIIc) may be associated with the risk of recurrent venous thromboembolism (VTE)...
  18. ncbi request reprint Pros and cons of new oral anticoagulants
    Kenneth A Bauer
    1Beth Israel Deaconess Medical Center and VA Boston Healthcare System, Department of Medicine, Harvard Medical School, Boston, MA
    Hematology Am Soc Hematol Educ Program 2013:464-70. 2013
    ..As practitioners gain familiarity with the drugs and healthcare systems adapt to their use, NOAC use will increase substantially over time. Warfarin, however, will continue to be an appropriate anticoagulant choice for many patients. ..
  19. doi request reprint Timing of postpartum enoxaparin administration and severe postpartum hemorrhage
    Rachel A Freedman
    Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Blood Coagul Fibrinolysis 19:55-9. 2008
    ..Severe postpartum hemorrhage is an infrequent complication when enoxaparin is administered to hemostatically intact women between 5 and 24 h following a vaginal delivery or 12-36 h following cesarean section...
  20. ncbi request reprint Selective inhibition of coagulation factors: advances in antithrombotic therapy
    Kenneth A Bauer
    VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Semin Thromb Hemost 28:15-24. 2002
    ..The availability of these agents and the continued development of investigational selective coagulation inhibitors have the potential to improve efficacy and decrease adverse events in patients at risk for VTE...
  21. ncbi request reprint New oral anticoagulants in development: potential for improved safety profiles
    Kenneth A Bauer
    Hematology Oncology Division, Beth Israel Deaconess Medical Center and VA Boston Healthcare System, Boston, MA, USA
    Rev Neurol Dis 7:1-8. 2010
    ..Studies suggest that they provide effective, predictable anticoagulation with a low bleeding risk and will potentially offer an improved clinical profile and wider safety margin compared with currently available therapies...
  22. ncbi request reprint Prothrombin activation is increased among asymptomatic carriers of the prothrombin G20210A and factor V Arg506Gln mutations
    K A Bauer
    Department of Medicine, Beth Israel Deaconess Medical Center and Boston VA Healthcare System, Harvard Medical School, Boston, MA 02115, USA
    Thromb Haemost 84:396-400. 2000
    ..This data provides conclusive evidence that heterozygosity for the prothrombin G20210A as well as the FV R506Q mutations in the general population leads to an increased rate of prothrombin activation in vivo...
  23. ncbi request reprint Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial
    M Cushman
    Department of Medicine, University of Vermont, Burlington, VT 05446, USA
    J Thromb Haemost 4:2199-203. 2006
    ..In some but not all studies, men with venous thrombosis had a higher risk of recurrence than women. Information on women with initial hormone-related thrombosis is scant...
  24. ncbi request reprint Obstetric complications in patients with hereditary thrombophilia identified using the LCx microparticle enzyme immunoassay: a controlled study of 5,000 patients
    Olivier Kocher
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Am J Clin Pathol 127:68-75. 2007
    ..These results confirm the association between genetic thrombophilia and selected obstetric complications...
  25. pmc The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size
    Jeffrey I Zwicker
    Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Blood 108:1280-3. 2006
    ....
  26. ncbi request reprint Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery
    K A Bauer
    Department of Medicine, Veterans Affairs Boston Healthcare System and Beth Israel Deaconess Medical Center, MA 02215, USA
    N Engl J Med 345:1305-10. 2001
    ..Despite thromboprophylaxis, major knee surgery carries a high risk of venous thromboembolism. Fondaparinux, the first of a new class of synthetic antithrombotic agents, may reduce this risk...
  27. ncbi request reprint Fondaparinux sodium: a selective inhibitor of factor Xa
    K A Bauer
    Hematology Section, VA Boston Healthcare System, Beth Israel Deaconess Medical Center, MA, USA
    Am J Health Syst Pharm 58:S14-7. 2001
    ..Fondaparinux sodium appears to meet the criteria for an ideal antithrombotic agent: equal or better effectiveness than currently available agents, a low bleeding risk, no need for laboratory monitoring, and once-daily administration...
  28. ncbi request reprint Management of thrombophilia
    K A Bauer
    VA Boston Healthcare System, Harvard Medical School, Boston, Massachusetts, USA
    J Thromb Haemost 1:1429-34. 2003
    ..Low-intensity warfarin therapy or novel anticoagulants such as oral direct thrombin inhibitors may prove effective strategies for preventing recurrent venous thromboembolism in patients with thrombophilia...
  29. ncbi request reprint Automated detection of the G20210A prothrombin mutation using the LCx microparticle enzyme immunoassay
    A Gilchrist
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, East Campus, 330 Brookline Avenue, Boston, MA 02215, USA
    Clin Chim Acta 314:249-54. 2001
    ..Several methods have been developed to detect the mutation; however, given the increased demand for this test in risk factor assessment, the development of simple and efficient screening methods has become necessary...
  30. ncbi request reprint A functional haplotype in the 5' flanking region of the factor VII gene is associated with an increased risk of coronary heart disease
    J A Carew
    Department of Medicine, VA Boston Healthcare System and Harvard Medical School, 1400 VFW Parkway, West Roxbury, MA 02132, USA
    J Thromb Haemost 1:2179-85. 2003
    ..The aim of this study was to investigate associations between coronary heart disease risk and polymorphisms in the coagulation factor (F)VII gene in participants of a large prospective study...
  31. ncbi request reprint ARP1 interacts with the 5' flanking region of the coagulation factor VII gene
    J A Carew
    VA Boston Healthcare System, Building 3, Room 2A106 151, 1400 VFW Parkway, West Roxbury, MA 02132, USA
    J Thromb Haemost 1:1220-7. 2003
    ..These data indicate a role for ARP1 in transcriptional modulation of the FVII gene...
  32. ncbi request reprint Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia
    J I Zwicker
    Hematology Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Thromb Haemost 2:2133-7. 2004
    ....
  33. pmc Stroke prevention in atrial fibrillation in older adults: existing knowledge gaps and areas for innovation: a summary of an American Federation for Aging research seminar
    Steven A Lubitz
    Cardiac Arrhythmia Service, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
    J Am Geriatr Soc 61:1798-803. 2013
    ..The opinions of those that participated in the meeting limit this report, which may not represent all of the questions that other experts in this field might raise. ..
  34. pmc Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy
    Jeffrey I Zwicker
    Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Clin Cancer Res 15:6830-40. 2009
    ..We evaluated the hypothesis that tumor-derived tissue factor-bearing microparticles in plasma contribute to cancer-associated thrombosis...
  35. ncbi request reprint Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors
    Kenneth A Bauer
    VA Boston Health System, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Cardiovasc Drug Rev 20:37-52. 2002
    ..In view of these collective findings, fondaparinux is expected to play a major role in the prevention and treatment of venous and arterial thrombotic disease...
  36. ncbi request reprint The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency
    Weei Yuarn Huang
    Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Transfusion 44:1562-6. 2004
    ..Recombinant activated factor VII (rFVIIa) is being tested to improve hemostasis in a variety of bleeding disorders. Clinical indications and efficacy are still being evaluated for this product...
  37. ncbi request reprint Assessment of hemostatic risk factors in predicting arterial thrombotic events
    David Feinbloom
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 25:2043-53. 2005
    ..However, the data on Factor VII, PAI-1, and platelet receptor polymorphisms are contradictory or lacking...
  38. ncbi request reprint Abnormal secretion and function of recombinant human factor VII as the result of modification to a calcium binding site caused by a 15-base pair insertion in the F7 gene
    F Peyvandi
    Hematology Section, Department of Medicine, VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA
    Blood 97:960-5. 2001
    ..These results demonstrate that a combination of secretion and functional defects is the mechanism whereby this insertion causes VII deficiency...
  39. doi request reprint Low molecular weight heparin to achieve live birth following unexplained pregnancy loss: a systematic review
    S Mantha
    Division of Hematology Oncology, Lahey Clinic, Burlington, MA, USA
    J Thromb Haemost 8:263-8. 2010
    ..A similar benefit for LMWH has also been proposed independent of thrombophilia status...
  40. ncbi request reprint Activation of the factor VII-tissue factor pathway
    K A Bauer
    Department of Medicine, Brockton West Roxbury Department of Veterane Affairs Medical Center, MA 02132, USA
    Thromb Haemost 78:108-11. 1997
    ..e., those with elevated levels of free factor VIIa, activation peptides of factor IX, factor X, or prothrombin) are more likely to develop arterial or venous thrombosis...
  41. ncbi request reprint Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies
    William D Fisher
    McGill University Health Centre, 1650 Cedar Avenue, Montreal, Quebec, H3G 1A4, Canada
    Thromb Haemost 97:931-7. 2007
    ..Overall, rivaroxaban total daily doses of 5-20 mg had the most favorable balance of efficacy and safety, relative to enoxaparin, for the prevention of VTE after major orthopaedic surgery...
  42. ncbi request reprint Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison
    Michael Rud Lassen
    Department of Orthopaedics, University Hospital of Copenhagen Hillerød, DK 3400, Hillerød, Denmark
    Lancet 359:1715-20. 2002
    ..We aimed to assess the ability of the pentasaccharide fondaparinux, the first of a new class of synthetic antithrombotic agents, to further reduce this risk...
  43. ncbi request reprint Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Jack Hirsh
    Henderson Research Centre, Hamilton Civic Hospitals, 711 Concession Street, Hamilton, Ontario, Canada
    Chest 133:141S-159S. 2008
    ..Three parenteral direct thrombin inhibitors and danaparoid are approved as alternatives to heparin in HIT patients...
  44. ncbi request reprint Coagulation activation and long-term outcome in acute coronary syndromes
    Diego Ardissino
    Division of Cardiology, Ospedale Niguarda Ca Grande, Milan
    Blood 102:2731-5. 2003
    ..25-2.28; RR, 1.35 and 95% CI, 1.11-1.86, respectively). After an episode of acute coronary syndrome, both high and low levels of thrombin generation are predictors of an increased risk of an unfavorable outcome...
  45. ncbi request reprint Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial
    Alexander G G Turpie
    Department of Medicine, General Division, Hamilton Health Sciences Corporation, Ontario, Hamilton, Canada
    Lancet 359:1721-6. 2002
    ..We aimed to see whether the pentasaccharide fondaparinux, the first drug of a new class of synthetic antithrombotic agents, could reduce this risk to a greater extent than other available treatments...
  46. ncbi request reprint Hormone replacement therapy and the factor V Leiden mutation
    Kenneth A Bauer
    Arterioscler Thromb Vasc Biol 22:879-80. 2002
  47. ncbi request reprint Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies
    Alexander G G Turpie
    Department of Medicine, Hamilton Health Sciences General Hospital, 237 Barton, Hamilton, Ontario, Canada L8L 2X2
    Arch Intern Med 162:1833-40. 2002
    ..Fondaparinux, the first of a new class of synthetic selective factor Xa inhibitors, may further reduce this risk compared with currently available thromboprophylactic treatments...
  48. ncbi request reprint Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees
    Arno H M Moons
    Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands
    Thromb Haemost 88:627-31. 2002
    ..These results suggest that rNAPc2 may be a promising therapeutic option to inhibit coagulation activation in patients with sepsis...
  49. ncbi request reprint Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders
    Richard D Press
    Department of Pathology and Medical Genetics, Oregon Health and Science University, Portland 97201, USA
    Arch Pathol Lab Med 126:1304-18. 2002
    ....
  50. ncbi request reprint A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery
    Alexander G G Turpie
    Department of Medicine, Hamilton Health Sciences General Hospital, Hamilton, Ontario, Canada
    J South Orthop Assoc 11:182-8. 2002
    ..4%. The overall incidence of clinically relevant bleeding was low and did not differ between the two groups. The benefit of fondaparinux was consistent across all types of surgery and all subgroups...
  51. ncbi request reprint Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism
    Paul M Ridker
    Center for Cardiovascular Disease Prevention and the Division of Preventive Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston 02215, USA
    N Engl J Med 348:1425-34. 2003
    ..0 and 3.0. However, for long-term management, no therapeutic agent has shown an acceptable benefit-to-risk ratio...
  52. ncbi request reprint Fondaparinux, the first selective factor Xa inhibitor
    Alexander G G Turpie
    Hamilton Health Sciences General Hospital, Hamilton, Ontario, Canada
    Curr Opin Hematol 10:327-32. 2003
    ..Finally, the efficacy and safety of fondaparinux in the treatment of venous thromboembolism and acute coronary syndromes appears promising...
  53. ncbi request reprint Fondaparinux and prevention of venous thromboembolism after orthopaedic surgery
    Alexander G G Turpie
    Lancet 362:1582-3. 2003
  54. ncbi request reprint New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies
    Alexander G G Turpie
    Department of Medicine, Hamilton Health Sciences General Hospital, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada
    Chest 124:371S-378S. 2003
    ..Fondaparinux has been recently approved for use in thromboprophylaxis after major orthopedic surgery. The clinical development of fondaparinux in other thromboprophylactic indications is ongoing...
  55. ncbi request reprint Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points
    Alexander G G Turpie
    Department of Medicine, Hamilton Health Sciences General Hospital, 237 Barton St East, Hamilton, ON, L8L 2X2, Canada
    Chest 126:501-8. 2004
    ....
  56. ncbi request reprint Fondaparinux
    Alexander G G Turpie
    Department of Medicine, Hamilton Health Sciences Hamilton General Hospital and McMaster University, Hamilton, Ontario, Canada
    J Am Acad Orthop Surg 12:371-5. 2004
  57. ncbi request reprint Two naturally occurring mutations on FVII gene (S363I-W364C) altering intrinsic catalytic activity
    Flora Peyvandi
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
    Thromb Haemost 88:750-5. 2002
    ....
  58. ncbi request reprint Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery
    Wolfgang Mueck
    Clinical Pharmacology, Bayer HealthCare AG, Aprather Weg 18a, Wuppertal, Germany
    Clin Pharmacokinet 47:203-16. 2008
    ....
  59. ncbi request reprint Venous thrombosis in the elderly: more questions than answers
    Roy L Silverstein
    Department of Cell Biology, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Blood 110:3097-101. 2007